Education
About Us
Working with TipRanks
Follow Us
MedinCell SA (FR:MEDCL)
:MEDCL
MEDCL Stock Chart & Stats
Day’s Range― - ―
52-Week Range€12.00 - €19.00
Previous CloseN/A
Volume18.50K
Average Volume (3M)54.41K
Market Cap
€495.04M
Enterprise Value€477.04M
Total Cash (Recent Filing)€21.28M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Jun 17, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.08
Shares Outstanding33,072,746
10 Day Avg. Volume40,746
30 Day Avg. Volume54,415
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)26.04
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€21.65Price Target Upside44.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
MedinCell SA News
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessTEV-44749 met its primary endpoint in the pivotal Phase 3 trial, showing statistically significant improvements in schizophrenia symptoms without major safety drawbacks.
Market SentimentUZEDY has enjoyed positive market sentiment and robust uptake since launch, with expectations for accelerated market penetration.
Product ApprovalApproval of UZEDY for treatment of bipolar disorder I could expand the addressable market and increase revenue streams through royalties.
Bears Say
Pipeline UncertaintyTeva should be well-positioned to file for approval of its second atypical antipsychotic long-acting injectable product based on MedinCell's technology, with potential U.S. approval and launch in 2026.
Valuation ConcernsInvestors should be aware that no contribution from the macozinone LAI candidate is included in the current valuation assessment.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.32%
Mutual Funds
― Other Institutional Investors
99.65% Public Companies and
Individual Investors
MEDCL FAQ
What was MedinCell SA’s price range in the past 12 months?
MedinCell SA lowest stock price was €12.00 and its highest was €19.00 in the past 12 months.
What is MedinCell SA’s market cap?
MedinCell SA’s market cap is €495.04M.
When is MedinCell SA’s upcoming earnings report date?
MedinCell SA’s upcoming earnings report date is Jun 17, 2025 which is in 51 days.
How were MedinCell SA’s earnings last quarter?
MedinCell SA released its earnings results on Dec 10, 2024. The company reported -€0.5 earnings per share for the quarter, missing the consensus estimate of -€0.19 by -€0.31.
Is MedinCell SA overvalued?
According to Wall Street analysts MedinCell SA’s price is currently Undervalued.
Does MedinCell SA pay dividends?
MedinCell SA does not currently pay dividends.
What is MedinCell SA’s EPS estimate?
MedinCell SA’s EPS estimate is -0.17.
How many shares outstanding does MedinCell SA have?
MedinCell SA has 33,072,746 shares outstanding.
What happened to MedinCell SA’s price movement after its last earnings report?
MedinCell SA reported an EPS of -€0.5 in its last earnings report, missing expectations of -€0.19. Following the earnings report the stock price went up 1.907%.
Which hedge fund is a major shareholder of MedinCell SA?
Currently, no hedge funds are holding shares in FR:MEDCL
---
Company Description
MedinCell SA
MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.
---
MEDCL Stock 12 Month Forecast
Average Price Target
€21.65
▲(44.62% Upside)
Technical Analysis
Best Analysts Covering MEDCL
1 Year
1 Year Success Rate
9/16 ratings generated profit
1 Year Average Return
+51.34%
reiterated a buy rating 2 months ago
Copying Nicolas Pauillac's trades and holding each position for 1 Year would result in 56.25% of your transactions generating a profit, with an average return of +51.34% per trade.
---